Literature DB >> 7283421

In vitro studies with Win 42122-2: comparison with gentamicin, netilmicin, and amikacin.

C C Sanders, W E Sanders.   

Abstract

The in vitro activity of Win 42122-2 against gram-negative clinical isolates was compared in serial twofold broth dilution tests with gentamicin, netilmicin, and amikacin. Against 173 gentamicin-susceptible Enterobacteriaceae, the activity of Win 42122-2 was generally twofold less than those of gentamicin or netilmicin and similar to that of amikacin. Against 60 gentamicin-susceptible nonfermentative gram-negative bacilli, including P. aeruginosa, the activity of Win 42122-2 was four- to eightfold less than that of gentamicin or netilmicin and two- to fourfold less than that of amikacin. Minimal bacterial concentrations for Win 42122-2 were usually similar to minimal inhibitory concentrations. Win 42122-2 was not highly active against gentamicin-resistant bacteria. Win 42122-2 was as active as gentamicin against Mycobacterium tuberculosis but was less active than gentamicin or amikacin against atypical mycobacteria. Win 42122-2 interacted synergistically with penicillin G against enterococci, including strains highly resistant to streptomycin.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7283421      PMCID: PMC181672          DOI: 10.1128/AAC.20.2.247

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Synergy of penicillin-netilmicin combinations against enterococci including strains highly resistant to streptomycin or kanamycin.

Authors:  C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1977-08       Impact factor: 5.191

2.  Susceptibility of organisms in the Mycobacterium fortuitum complex to antituberculous and other antimicrobial agents.

Authors:  W E Sanders; E C Hartwig; N J Schneider; R Cacciatore; H Valdez
Journal:  Antimicrob Agents Chemother       Date:  1977-08       Impact factor: 5.191

Review 3.  Plasmid-determined resistance to antimicrobial agents.

Authors:  J Davies; D I Smith
Journal:  Annu Rev Microbiol       Date:  1978       Impact factor: 15.500

4.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

5.  Activity of gentamicin against mycobacteria in vitro and against Mycobacterium tuberculosis in mice.

Authors:  W E Sanders; R Cacciatore; H Valdez; I Pejovic; F P Dunbar
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

6.  Biological activity of netilmicin, a broad-spectrum semisynthetic aminoglycoside antibiotic.

Authors:  G H Miller; G Arcieri; M J Weinstein; J A Waitz
Journal:  Antimicrob Agents Chemother       Date:  1976-11       Impact factor: 5.191

7.  Comparative nephrotoxicities of netilmicin and gentamicin in rats.

Authors:  F C Luft; M N Yum; S A Kleit
Journal:  Antimicrob Agents Chemother       Date:  1976-11       Impact factor: 5.191

8.  Mutational biosynthesis by idiotrophs of Micromonospora purpurea. I. Conversion of aminocyclitols to new aminoglycoside antibiotics.

Authors:  D Rosi; W A Goss; S J Daum
Journal:  J Antibiot (Tokyo)       Date:  1977-01       Impact factor: 2.649

9.  In vitro studies with Sch 21420 and Sch 22591: activity in comparison with six other aminoglycosides and synergy with penicillin against enterococci.

Authors:  C C Sanders; W E Sanders; R V Goering
Journal:  Antimicrob Agents Chemother       Date:  1978-08       Impact factor: 5.191

10.  Comparative nephrotoxicity of aminoglycoside antibiotics in rats.

Authors:  F C Luft; R Bloch; R S Sloan; M N Yum; R Costello; D R Maxwell
Journal:  J Infect Dis       Date:  1978-10       Impact factor: 5.226

View more
  1 in total

Review 1.  Netilmicin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; S Chaplin; R H Sayce; K L Goa
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.